The company said that shipment of these products has commenced.
As the first company to file an abbreviated new drug application (ANDA) with a Paragraph IV patent certification for granisetron hydrochloride injection, 1mg (base)/mL in 1mL single-dose vials, Teva said that it has been awarded 180 days marketing exclusivity for this product.